Apogee's strategy involves first launching a best-in-class monotherapy and then following up with combination therapies (e.g., IL-13 + OX40L). This mirrors successful strategies from companies like Vertex in Cystic Fibrosis and Gilead in HIV, aiming to capture different patient segments and build a durable franchise within atopic dermatitis.

Extending a wearable's wear time has two major benefits beyond convenience. It lowers costs by reducing device waste and the need for frequent healthcare worker assistance. More importantly, it dramatically increases patient compliance, as a once-a-month application is far easier to adhere to than a daily routine.

Despite Dupixent's dominance, Apogee's CEO claims the atopic dermatitis market has so much unmet need that new drugs with even limited differentiation are achieving blockbuster status. This suggests the market is expanding to accommodate new entrants, rather than being a zero-sum game of stealing market share.

Instead of targeting new biological pathways, Apogee enhances proven antibody therapies by extending their half-life. This shifts the competitive battleground from pure scientific discovery to patient adherence and lifestyle, aiming for quarterly or semi-annual dosing versus the current bi-weekly standard for market leaders.

A major challenge in managing high cholesterol is patient adherence to daily medication for life. New therapies like Inclisiran use mRNA silencing and require only two injections per year, dramatically improving adherence for busy or non-compliant individuals.

For RNAi and antisense therapies targeting chronic conditions like cardiovascular disease, the critical competitive advantage is durability, not just efficacy. The ability to offer infrequent dosing, such as twice-yearly injections, represents a significant step-change from daily medications and is the key factor expected to drive market adoption.

Due to soquelitinib's prolonged effect, which 'resets' the immune system long after the drug is cleared, the CEO envisions it as an intermittent therapy. This would move away from the standard daily-for-life treatment model for autoimmune diseases like atopic dermatitis, representing a potential 'holy grail' for treatment.

When asked about complex antibodies like ADCs and bispecifics, GSK's CSO emphasizes that extending a drug's duration is a primary innovation. He highlights a severe asthma treatment dosed just twice a year as a prime example of creating significant patient value before adding further engineering complexity.

Faced with a competitor's once-monthly dosing schedule versus their own weekly one, Vera's CEO strategically downplays frequency as a key differentiator. He emphasizes their drug's easy-to-use autoinjector, low volume, and high patient adherence, framing the weekly schedule as a minor detail within a superior overall patient experience.